Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 57, 332-336, January 15, 1997]
© 1997 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gorelik, E.
Right arrow Articles by Galili, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorelik, E.
Right arrow Articles by Galili, U.

Reduction of Metastatic Properties of BL6 Melanoma Cells Expressing Terminal Fucose{alpha}1-2-Galactose after {alpha}1,2-Fucosyltransferase cDNA Transfection1

Elieser Gorelik2, Fan Xu, Timothy Henion, Farvardin Anaraki and Uri Galili

University of Pittsburgh Cancer Institute and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 [E. G., F. X.]; and Department of Microbiology and Immunology, Medical College of Pennsylvania-Hahnemann School of Medicine, Allegheny University, Philadelphia, Pennsylvania 19129 [T. H., F. A., U. G.]

We reported previously that transfection of BL6 melanoma cells that do not express the {alpha}1,3-galactosyltransferase ({alpha}1,3GT) gene with the {alpha}1,3GT cDNA resulted in synthesis and expression of {alpha}-galactosyl epitopes (Gal{alpha}1-3Galß1-4GlcNAc-R) and an impairment of their metastatic potentials. It was of interest to test whether inhibition of metastatic properties of BL6 melanoma cells is specifically associated with the appearance of the terminal {alpha}-Gal or whether capping N-acetyllactosamine with another oligosaccharide would also affect the metastatic properties of BL6 melanoma cells. For this purpose, BL6-2 clone isolated from B16BL6 melanoma was transfected with the {alpha}1,2-fucosyltransferase ({alpha}1,2FT) cDNA. The {alpha}1,2FT catalyzes a transglycosylation reaction, resulting in syntheses of the Fuca{alpha}1-2Galß1-4GlcNAc-R structure, which is known as the H antigen of O blood group in humans and is also synthesized in some cells of mice. Transfection of BL6 melanoma cells with the {alpha}1,2FT cDNA resulted in the appearance of the terminal Fuc{alpha}1-2Galß1-4GlcNAc-R epitopes reacting with the Ulex europaeus agglutinin lectin. In parallel, the transfected cells showed a decrease in N-acetyllactosamine sialylation. Decline in sialylation of the transfected cells is likely to be the result of competition between {alpha}1,2FT and {alpha}2,3- or {alpha}2,6-sialyltransferases for the common substrate N-acetyllactosamine (Galß1-4GlcNAc-R) on N-linked carbohydrate chains of glycoproteins and glycolipids. The {alpha}1,2FT-transfected BL6-2 cells showed an increase in homotypic aggregation. In parallel, metastatic ability of the {alpha}1,2FT-transfected BL6-2 cells was reduced significantly in the immunocompetent as well as immunosuppressed (X-irradiated) mice. Thus, these data imply that capping N-acetyllactosamine with {alpha}Gal or {alpha}Fuc and the corresponding reduction in sialylation of BL6-2 melanoma cells were associated with reduction of their metastatic potential.

1 This study is supported by NIH Grant CA59903.

2 To whom requests for reprints should be addressed, at Biomedical Science Tower, W954, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213. Phone: (412) 624-0346; Fax: (412) 624-7736.

Received 8/26/96. Accepted 11/13/96.




This article has been cited by other articles:


Home page
J. Immunol.Home page
E. Assa-Kunik, D. Fishman, S. Kellman-Pressman, S. Tsory, S. Elhyany, O. Baharir, and S. Segal
Alterations in the Expression of MHC Class I Glycoproteins by B16BL6 Melanoma Cells Modulate Insulin Receptor-Regulated Signal Transduction and Augments Resistance to Apoptosis
J. Immunol., September 15, 2003; 171(6): 2945 - 2952.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Oda, T. Senaha, Y. Matsuno, K. Nakajima, R. Naka, M. Kinoshita, E. Honda, I. Furuta, and K. Kakehi
A New Fungal Lectin Recognizing {alpha}(1-6)-linked Fucose in the N-Glycan
J. Biol. Chem., August 22, 2003; 278(34): 32439 - 32447.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Aubert, L. Panicot, C. Crotte, P. Gibier, D. Lombardo, M.-O. Sadoulet, and E. Mas
Restoration of {{alpha}}(1,2) Fucosyltransferase Activity Decreases Adhesive and Metastatic Properties of Human Pancreatic Cancer Cells
Cancer Res., March 1, 2000; 60(5): 1449 - 1456.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
M. Eckhardt, B. Gotza, and R. Gerardy-Schahn
Mutants of the CMP-sialic Acid Transporter Causing the Lec2 Phenotype
J. Biol. Chem., August 7, 1998; 273(32): 20189 - 20195.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1997 by the American Association for Cancer Research.